People
Five months after Be Biopharma launched with $52 million in Series A financing, the company tapped bluebird bio veteran Joanne Smith-Farrell as its new chief executive officer.
Aron Knickerbocker, former Chief Executive Officer (CEO) of RayzeBio and Five Prime Therapeutics, has taken the helm of Aulos Bioscience, a relatively new biotech company focused on the development of highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies the treatment of solid tumors.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
It has been one year since COVID-19 was declared a global pandemic. In that time, more than 118 million people have contracted the virus and 2,622,190 people, including 529,267 in the United States, have died as a result.
GlaxoSmithKline failed to hit a key internal profit goal in 2020, due in large part to the impact of the COVID-19 pandemic. As a result, Chief Executive Officer Emma Walmsley took a nearly $2 million hit to her annual compensation.
Doudna, the subject of a new book by Walter Isaacson titled “The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race,” has kept busy.
Despite a historic push for greater diversity and inclusion (D&I), a significant disconnect prevails between good intentions and actual lived experiences.
In the wake of an increasingly accelerated COVID-19 vaccine rollout, the CDC has released new guidance statements that give fully vaccinated individuals more freedom to socialize and participate in pre-pandemic activities.
It didn’t take long for Jason Campagna to find a new role after departing Intercept Pharmaceuticals last month. Campagna will take on the role of chief medical officer for Q32 Bio.
Scott Garland, the former chief executive officer of Portola Pharmaceuticals, will become the next CEO of South San Francisco-based PACT Pharma.
PRESS RELEASES